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therapy at DLC. 20.3% of these patients had stopped PCP
prophylaxis. One patient had PCP requiring hospital admis-
sion 146 days after HCT. This patient received myeloablative
conditioning with ATG followed by mismatched unrelated
donorHCT. At timeof PCP infection, patientwas on tacrolimus
and 40mg of prednisone for GVHD treatment and was
receiving pentamidine for PCP prophylaxis.
In summary, the incidence of PCP is rare in the post alloHCT
population. Our data suggests PCP prophylaxis can be safely
discontinued if CD4+ counts > 200/uL and if not on systemic
steroids.Pre-restrictive Approach Restrictive Approach
Day 100 Mortality 2/100 3/100
1-year Mortality 11/100 8/100313
Safety of Coadministaraion of Teicoplanin and
Tacrolimus After Allogeneic Hematopoietic Stem Cell
Transplantation
Takehiko Mori, Jun Kato, Akiko Yamane, Sumiko Kohashi,
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Background: Tacrolimus has been widely used for the
prophylaxis or treatment of graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation
(HSCT). Among its side effects, nephrotoxicity is often clini-
cally problematic. Recipients of HSCTare highly susceptible to
the infectiondue todrug-resistant grampositivebacteria, and
thus nephrotoxic glycopeptide antimicrobial agents such as
teicoplanin and vancomycin are often administered. Since the
nephrotoxicity of coadministration of teicoplanin and tacro-
limus has yet to be evaluated, it was retrospectively evaluated
in the setting of allogeneic HSCT.
Patients & Methods: Recipients of allogeneic HSCT for
hematological diseases who received intravenous teicopla-
nin for more than 4 days during the continuous intravenous
infusion of tacrolimus within 30 days after transplantation
were selected from the data base. Patients who received
liposomal amphotericin-B or foscarnet were excluded. The
data including patient demographics, whole blood concen-
tration of tacrolimus, dose and duration of teicoplanin
administration, and serum creatinine (sCr) were collected.
Therapeutic drug monitoring of tacrolimus and teicoplanin
was performed in all the patients.
Results: Sixty-seven patients fulﬁlled criteria, and were
included in the analysis. Median age of the patients was 48
years (range: 16-62), and median duration of the coadmin-
istration of teicoplanin and tacrolimus was 11 days (range: 4-
40). Mean whole blood concentration of tacrolimus during
teicoplanin administration were 16.3+1.7 ng/ml. Twice or
greater increases of sCr compared with that before initiating
teicoplanin were observed only in 2 (3.0%) of 67 patients.
Nephrotoxicity was reversible andmanageable in all cases by
discontinuation of teicoplanin with or without dose adjust-
ment of tacrolimus.
Conclusion: Teicoplanin can safely be coadministered with
tacrolimus even in the early post-transplant period under
the appropriate management with therapeutic drug moni-
toring of each drug.314
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Introduction: The beneﬁts of a restrictive transfusion
approach (i.e. improved survival/ decreased infections) have
been demonstrated in a variety of hospitalized patient pop-
ulations. There are little data in the oncology setting outside
of the transplantation programs successfully treating
Jehovah Witnesses, who generally decline blood product
support. The University of Alabama at Birmingham adopted
a hospital wide restrictive transfusion policy in February,
2008; speciﬁcally in non-bleeding patients, the threshold for
transfusion is 7 g/dl and 1 unit of red cells is to be transfused
and the patient reassessed prior to considering additional
transfusions. Our stem cell transplant program adopted this
policy with the exception that patients with diastolic/systolic
dysfunction were maintained at a higher hemoglobin.
Objective: The purpose of this outcome analysis is to review
the impact of a restrictive red cell transfusion approach in
multiple myeloma patients undergoing autologous PBSC
transplant.
Materials and methods: We collected data for 200 multiple
myeloma subjects: 100 patients transplanted in 2005-2007
were compared to 100 patients who underwent trans-
plantation utilizing the restrictive transfusion policy (2009-
2011). Initial analysis included Day 100 and 1- year mortality
recognizing that the latter could be inﬂuenced bymany other
factors, including disease recurrence.
Results/Conclusion: Day 100 and 1- year mortality were not
adversely affected by the adoption of a restrictive transfusion
approach. A statistical difference was not expected as the
mortality associated with auto PBSC for multiple myeloma is
low. Further analysis of our entire multiple myeloma pop-
ulation will be presented. Analysis will include the impact of
a restrictive transfusion approach on transplant-related co-
morbidities, particularly infections. Additionally, we will
compare the number of blood products utilized in these 2
cohorts.315
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Background: HFS, an adverse reaction associated with
certain chemotherapeutic agents, is characterized by dyses-
thesias in hands and feet. No cases of HFS with total body
Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278 S269irradiation (TBI) or etoposide (VP16) have been reported in
the literature, but a few cases have been reported with
palifermin.
Objective: To determine the incidence, onset, duration,
severity and risk factors for HFS in patients receiving TBI/
VP16  palifermin, and to evaluate the effects of palifermin
on the development of HFS.
Method: An institutional review board-approved retro-
spective cohort study of adult allogeneic HSCT patients at
City of Hope receiving TBI/VP16 (control) and TBI/VP16/pal-
ifermin (palifermin) was conducted during 2 speciﬁc time
periods. The occurrence of HFS was determined through
review of medical records.
Results: Incidence of HFS was 38% and 40% in the control
(n¼58) and palifermin (n¼58) groups (Fisher's exact, P¼ .85).
Mean duration of HFS was 16.8 and 11 days (t-test, P ¼ .015).
Mean onset of HFS occurred on day +7.6 and +3.7 (t-test, P ¼
.0001). SevereHFSoccurred in43%and13% (Fisher's exact, P¼
.07). Severity of HFS was associated with duration in the
palifermin group (Spearman r¼0.85, P < .0001). Females and
patients who developed early skin reactions to palifermin
weremore likely todevelopHFS (Fisher's exact,P¼ .01 andP¼
.04). Age, donor type, and palifermin dosing schedule were
not risk factors for development of HFS.
Conclusion: TBI/VP16 was associated with a 38-40% inci-
dence of HFS. Palifermin signiﬁcantly reduced time to onset
and decreased duration of HFS and offers a previously unre-
ported beneﬁt in this patient population. Female gender and
early skin reaction to palifermin were risk factors for HFS.
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Introduction: Infection remains a major challenge in
patients undergoing stem cell transplants in developing
countries. The Tata medical Center (TMC) is a new compre-
hensive cancer center in Eastern India started in May 2011.
This abstract reviews the gut surveillance cultures for multi-
drug resistant organisms (MDROs) in our transplant patients
(SCT) in the ﬁrst 10 months of operation.
Materials and Methods: From Dec 2011 to early October
2012, information on patients undergoing SCT was reviewed.
Indications for transplant included malignant [AML, MDS,
NHL, Myeloma, Hodgkin Lymphoma] and non-malignant
conditions [Thalassemia, Aplastic Anemia, Fanconi Anemia].
Fecal Surveillance cultures were taken prior to SCT and were
carried out by a method based on Landman D et al (J Clin
Microbiol 2005). All patients received anti-fungal (pos-
aconazole in 12/21) and anti-viral prophylaxis (acyclovir 21/
21). Patients were treated in HEPA ﬁltered rooms and febrile
episodes managed as per institutional policy, initiating
therapy with amikacin and piperacillin-tazobactum.
Results and Discussion: 21 patients [16 male and 5 female]
underwent 22 hematopoietic stem cell transplant proce-
dures [15 allogeneic and 7 autologous]. Allogeneic trans-
plants included 11 matched related donor, 2 matched
unrelated donor and 2 haploidentical transplants. Medianage was 26yr [range: 6yr-60yr]. Surveillance culture was
done in 19 patients and MDROs were detected all patients.
Multiple MDRO strains were found in 11/19 patients. ESBL,
MBL and AmpC producing organisms were found in 17/19, 4/
19 and 5/19 patients respectively. Fever was documented in
all transplant patients and 15 of 213 blood cultures drawn
were positive with eight signiﬁcant isolates among which
was an MDRO Pseudomonas aeruginosa. Transplant related
mortality in three patients was attributed to sepsis in two
(pneumonia due to Aspergillus fumigatus, and Elizabethkingia
meningoseptica)and GVHD in one patient. Antimicrobial
therapy was escalated to Meropenem in 19/22, Colistin in 8/
22, Teicoplanin in 10/22, Metronidazole in 9/22, Liposomal
Amphotericin-B in 4/22, and Caspofungin in 5/22. In the 8
patients given colistin, carbapenamase positive organisms
were documented in surveillance cultures of 4.
Conclusions: The high level of antimicrobial resistance in
the enteric ﬂora of patients undergoing SCT in the devel-
opingworldwill have a signiﬁcant impact on antibiotic usage
and outcome.317
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The dose limiting toxicity of high dose melphalan condi-
tioning for autologous stem cell transplantation (HDM-ASCT)
in patients with plasma cell dyscrasias (PCD) is mucositis of
the upper and lower gastrointestinal tract. Mucositis can lead
to decreased oral intake, increased length of stay (LOS) and
gut-derived infections. Studies with transplant recipients
have shown conﬂicting results regarding the efﬁcacy of the
amino acid glutamine and the probiotic yeast Saccharomyces
boulardii (GSB) for mucositis attenuation, improvement in
gut immune barrier function, and modulation of inﬂamma-
tory cytokines. We sought to evaluate the beneﬁt of GSB on
mucosal morbidity and incidence of diarrhea at our institu-
tion, where 151 patients with PCD were transplanted
between January 2011 and July 2012.
For this retrospective casecontrol study, inclusioncriteriawere
patients with multiple myeloma and AL amyloidosis who
received HDM-ASCT either as consolidation of front-line
therapy or salvage. At our institution, based on referring
physician group preference, one group of patients with PCD
was routinely prescribed GSB while another group was not.
The 75 patients receiving supplementationwere prescribed to
take daily L-glutamine for 2 weeks, leaving a 4-day pause
before the transplant date, and daily Saccharomyces boulardii
for 2 weeks prior to the transplant, until the day of admission,
witha costofUSD83.The remaining76patientsdidnot receive
GSB. As per institutional standard of care, all subjects received
cryotherapyduringHDMinfusion for prophylaxis ofmucositis.
The charts of the 151 patients (86 males, 65 females) aged
27 - 72 years (median 61 years) who received HDM-ASCT
between January 2011 and July 2012 were reviewed. Inci-
dence of mucositis in the GSB group was 30.7% vs 34.2% in
the no GSB group. Severe mucositis, deﬁned as preventing
oral intake, occurred in 10.1% of the GSB group and 17.1% of
the no GSB group. Incidence of diarrhea in the 2 groups was
86.7% and 81.6%, in the OGP group and no GSB group,
